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Introduction
Protein disulfide isomerases (PDIs) catalyze disulfide bond for­
mation in itinerant proteins in the ER, promoting protein folding 
in the secretory pathway. In the process, the PDIs are reduced 
by their ER clients and must be reoxidized to sustain disulfide 
bond formation. In yeast, PDI reoxidation is performed by the 
enzyme ERO1 (ER oxidoreductin 1). Thus, electrons recovered 
from reduced cysteines on polypeptides that are translocated 
into the lumen of the yeast ER are channeled to their ultimate 
acceptor in a relay involving the luminal PDIs and ERO1 (for 
reviews see Tu and Weissman, 2004; Sevier and Kaiser, 2008).
Yeast and simple metazoans such as worms and flies have 
a single copy of the ERO1 gene, which is essential (Frand and 
Kaiser, 1998; Pollard et al., 1998; Tien et al., 2008). In contrast, 
mammals have two genes encoding proteins homologous to 
yeast Ero1p, known as ERO1- (or Ero1l; Cabibbo et al., 2000) 
and ERO1- (or Ero1lb; Pagani et al., 2000). Conservation of 
key residues involved in enzymatic activity and its regulation 
and mammalian overexpression studies and trans­specific com­
plementation experiments leave little room for doubt that the   
 isoform of the mammalian enzyme is able to promote disulfide 
bond formation in the ER (Cabibbo et al., 2000; Mezghrani et al., 
2001; Appenzeller­Herzog et al., 2008; Baker et al., 2008). 
ERO1­’s role in disulfide bond formation in mammals is   
further supported by the observation that its mRNA is found in 
many tissues (Cabibbo et al., 2000) and by the diverse conse­
quences of experimental attenuation of the enzyme’s level of 
expression (for examples see May et al., 2005; Qiang et al., 
2007; Li et al., 2009).
The  isoform is less well characterized, and its expression 
pattern is less well understood. An earlier study has called atten­
tion to the role of ER stress, which is a physiological condition 
arising from a mismatch between ER unfolded protein load and 
the  organelle’s  capacity  to  cope  with  such  load,  in  activating 
ERO1­ expression via the so­called unfolded protein response 
(UPR; Pagani et al., 2000). More recently, a study has called atten­
tion to the high basal levels of ERO1­ protein in the pancreatic 
islets of Langerhans (Dias­Gunasekara et al., 2005), suggesting a 
measure of tissue specificity to the protein’s expression.
M
ammals have two genes encoding homologues 
of  the  endoplasmic  reticulum  (ER)  disulfide 
oxidase ERO1 (ER oxidoreductin 1). ERO1- is 
greatly enriched in the endocrine pancreas. We report 
in this study that homozygosity for a disrupting allele of 
Ero1lb selectively compromises oxidative folding of pro-
insulin and promotes glucose intolerance in mutant mice. 
Surprisingly, concomitant disruption of Ero1l, encoding 
the other ERO1 isoform, ERO1-, does not exacerbate the 
ERO1- deficiency phenotype. Although immunoglobulin-
producing cells normally express both isoforms of ERO1, 
disulfide bond formation and immunoglobulin secretion 
proceed at nearly normal pace in the double mutant. 
Moreover,  although  the  more  reducing  environment  of 
their ER protects cultured ERO1- knockdown Min6 cells 
from the toxicity of a misfolding-prone mutant Ins2
Akita, 
the diabetic phenotype and islet destruction promoted 
by Ins2
Akita are enhanced in ERO1- compound mutant 
mice. These findings point to an unexpectedly selective 
function for ERO1- in oxidative protein folding in insulin- 
producing cells that is required for glucose homeostasis 
in vivo.
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cells of the islets of Langerhans are especially sensitive to the 
consequences of ER stress and the attendant oxidative stress (for   
review see Eizirik et al., 2008). Thus, the proposed induction of 
ERO1­ by the UPR (Pagani et al., 2000) and the report of its   
selective expression in the islets of Langerhans (Dias­Gunasekara 
et al., 2005) raised our curiosity as to the functional significance 
In simple eukaryotes such as yeast and worms, partial   
lowering of ERO1 activity promotes resistance to the lethal   
effects of high levels of ER stress (Haynes et al., 2004; Marciniak 
et al., 2004), and in worms, knockdown of that species’ single 
isoform, ero-1, in postembryonic animals significantly prolongs 
adult lifespan (Curran and Ruvkun, 2007). The insulin­producing   
Figure 1.  ERO1- is a disulfide oxidase selectively expressed 
in the pancreas. (A) Immunoblot of mouse tissue detergent   
extracts reacted with antisera raised to ERO1- (top), ERO1- 
(middle), and Ribophorin I (bottom; an ER recovery marker). 
Note the selective expression of ERO1- in the pancreas and 
the  cross-reactivity  of  the  anti–ERO1-  serum  with  ERO1- 
(also see Fig. S1). The asterisk marks a nonspecific band 
reactive with the anti–ERO1- serum in pancreatic lysates. 
(B) ERO1- immunoblot of membrane fraction derived from 
mouse secretory tissues. PDI serves as a recovery marker.   
(C) Immunoblot of ERO1- content of pancreatic membrane 
fraction (Mem Fr) derived from the indicated tissue volume 
and of known amounts of purified, bacterially expressed pro-
tein (ERO1-
r). The relative signal intensity (rel signal) is noted 
under the blot. (D) In vitro disulfide oxidase activity of bacte-
rially expressed mouse ERO1- (ERO1-
r), mouse ERO1-, 
or mouse ERO1- purified from transfected 293T cells, using 
bacterially expressed reduced human PDI or reduced E. coli 
thioredoxin (TrxA) as substrates and H2O2 production (read 
kinetically in a fluorescence-based assay) as a readout. The 
time-dependent increase in fluorescence of each sample is 
reported on over a period of 60 min (t). The inset shows a 
Coomassie-stained gel of the purified enzymes (see Fig. S2 
for  additional  technical  control  experiments  validating  the   
assay). RFU, relative fluorescent unit. (A–D) Molecular mass is 
indicated in kilodaltons.823 Islet dysfunction in Ero1lb mutant mice • Zito et al.
of ERO1­ expression under normal conditions and under con­
ditions of ER stress. Therefore, we have studied mice with severe 
disruption of ERO1­ expression and report on their phenotype   
under basal conditions, under conditions of cocompromised 
ERO1­ expression, and under conditions of severe ER stress in 
the insulin­producing cells of the islets of Langerhans.
Results
Pancreatic-selective expression  
of ERO1- and its disruption by  
the P077G11 insertion
To revisit the tissue expression of ERO1 isoforms, we raised rab­
bit polyclonal antisera to the  and  mouse proteins. Immuno­
blotting of mouse tissue extracts revealed a very strong signal 
of ERO1­ in the pancreas. In contrast, an ERO1­ signal was 
found in all tissues tested (Fig. 1 A and Fig. S1). The ERO1­ 
signal was concentrated in the membrane fraction of expressing   
cells, as previously described (not depicted; Pagani et al., 2000),   
and analysis of the membrane fraction from several secre­
tory tissues confirmed the pancreatic­selective expression of the   
protein (Fig. 1 B). Quantitative immunoblotting of the ERO1­  
content in purified membrane fraction of pancreatic tissue 
and calibration with the signal derived from known amounts 
of bacterially expressed ERO1­ indicated that the protein’s 
concentration in pancreatic ER fraction was in the order of   
12 ng/µl (Fig. 1 C). Given a predicted molecular mass of 50 kD, 
the estimated concentration of the protein in the ER is at least 
0.24 µM, which is a high concentration for an enzyme. This 
calculation is based on a conservative assumption that the tis­
sue is 50% cellular and that the ER is 50% of the cell’s volume 
and ignores the fact that ERO1­ expression is largely limited 
to the islets of Langerhans (Fig. 2 C). The relatively high level 
expression of ERO1­ in the pancreas and cross­reactivity of 
the anti–ERO1­ sera with ERO1­ (Fig. S1) also account for 
significant ERO1­ signal in the pancreatic lysate probed with 
the ERO1­ antiserum (Fig. 1 A, lane 1).
To date, ERO1­’s enzymatic function had been inferred 
from sequence conservation with yeast Ero1p but had not been 
demonstrated experimentally. To critically examine this infer­
ence, ERO1­’s ability to oxidize disulfide isomerases was 
measured by an in vitro fluorescent assay that detects the H2O2 
produced as ERO1 passes the electron it accepts from its reduced 
substrates to molecular oxygen (Gross et al., 2006). The addi­
tion of Flag­tagged mouse ERO1­ or ­, purified from trans­
fected 293T cells, to the assay resulted in a time­dependent 
increase in H2O2 production. Both isoforms of ERO1 had roughly 
similar activity in this assay, resembling that of recombinant 
Figure 2.  ERO1- disruption by promoter trap insertion into the Ero1lb  
locus. (A) Ethidium bromide–stained agarose gel of genomic DNA recov-
ered by PCR from the Ero1lb (ERO1-) locus after digestion with PstI. Shown 
are samples of F2 progeny of C57BL/6; 129 F1 hybrid parents hetero-
zygous for the ERO1- insertion allele (i/+) from the P077G11 ES cell 
line and wild-type C57BL/6 and 129 DNA. Note that the mutant allele (i)   
tracks with the 129 version of the polymorphism, to which it is tightly linked. 
(B) ERO1- immunoblot of membrane fraction of pancreas of wild-type 
(+/+), heterozygous (i/+), and homozygous ERO1- mutant mice (i/i).   
The asterisk marks the ERO1-–Ceo fusion protein encoded by the trapped 
insertion  allele.  Ribophorin  I  and  immunoglobulin-binding  protein  (BIP) 
serve as ER recovery markers. (C) Fluorescent micrographs of frozen sec-
tion of pancreas from wild-type (+/+) and ERO1- homozygous mutant 
mice (i/i) stained with antisera to insulin (Ins), ERO1-, and the karyophilic 
dye DAPI. The bottom right panel in each genotype is an overlay of the 
three stains. Note the colocalization of insulin and ERO1-. Bar, 100 µm.
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pancreatic sections confirmed the previously described heavy 
islet staining of ERO1­ in the wild­type mice (the islets 
are recognized by insulin immunostaining; Dias­Gunasekara   
et al., 2005) and its absence from the homozygous mutant 
(i/i) mice (Fig. 2 C).
Impaired glycemic control and defective 
insulin biogenesis in ERO1- mutant mice
Wild­type and mutant mice of both sexes were indistinguish­
able superficially, and all three genotypes were recovered at 
the expected frequency in the progeny of heterozygous (i/+)   
matings. To gauge the effect of the mutation on glycemic control, 
we compared the fasting blood sugar in F2 male siblings that 
were wild type, heterozygous, or homozygous for the mutation. 
By 3 mo of age, the majority of the homozygous mutant mice 
had a stable diabetic phenotype with mild fasting hyperglycemia   
(Fig. 3 A). The ratio of glucose to insulin was dramatically 
elevated in the homozygous mutant mice, which is consistent 
with a defect in insulin production/secretion (Fig. 3 B). Fasted 
heterozygous  mutant  mice  had  wild­type  glucose  levels  but 
were relatively impaired in their ability to assimilate a glu­
cose load in a glucose tolerance test (Fig. 3 C). This defect, 
too, was associated with an abnormally elevated glucose/insulin   
ratio (Fig. 3 D).
The mild diabetic phenotype of the ERO1- mutant mice 
was not associated with conspicuous histological changes in the 
islets of Langerhans (Fig. 4 A). However, insulin content in the 
pancreas of mutant mice was significantly decreased (Fig. 4 B 
and Fig. S3), and subtle disorganization of the islets, reflected in 
the abundance of glucagon­positive cells in their centers, was 
noted (Fig. 4 C). Ultrastructure of insulin­producing  cells from 
the homozygous mutant mice was likewise normal, except for a 
trend toward increased content of ER lamella. Conspicuously 
absent were cells with dilated ER, which are observed in other 
mouse models of defective protein folding in the ER (Fig. 4 D).
Proinsulin folds oxidatively (Anfinsen, 1973), and correct 
placement of three disulfide bonds is critical to the protein’s 
maturation in the ER (Wang et al., 1999). Pulse­chase metabolic 
labeling of newly synthesized protein in islets recovered from 
wild­type and homozygous mutant mice followed by immuno­
precipitation of the labeled proinsulin and insulin from the cell 
lysate and the culture supernatant revealed a reproducible delay 
in the conversion of proinsulin to insulin (Fig. 5, A and B). This 
delay was associated with the notable persistence of high mol­
ecular mass (presumably oxidized) aberrant intermediates of 
proinsulin in the mutant cells (Fig. 5, C and D). A delay in pro­
insulin maturation was also observed in ERO1­ knockdown in 
cultured Min6 cells, an insulin­producing  cell line (Fig. S5).
Nonredundancy of the ERO1 isoforms 
in the endocrine pancreas and 
immunoglobulin-secreting cells
The aforementioned observations suggest that ERO1­ loss of 
function has an adverse effect on insulin biogenesis and glyce­
mic control in mice. To determine whether ERO1­ comple­
ments the activity of the  isoform and accounts for the residual 
oxidative capacity of the insulin­producing cells from the ERO1­ 
mouse ERO1­ produced in bacteria (Fig. 1 D). Both enzymes 
had similar relative ability to accept electrons from a model 
substrate, reduced bacterial thioredoxin, and from a physiologi­
cal  substrate,  reduced  human  PDI.  An  active  site  mutation 
ERO1­
C396A abolished all enzymatic activity in vitro (Fig. S2), 
as predicted (Mezghrani et al., 2001), and only background levels 
of H2O2 production were noted in the absence of substrate, at­
testing to the specificity of the assay.
The aforementioned observations confirmed the pancreatic­
selective expression of ERO1­ and established definitively its 
ability to directly oxidize reduced PDI. To gain further insight 
into the physiological role of ERO1­, we developed a mouse 
model with a loss of function mutation in the gene.
The P077G11 embryonic stem (ES) line contains an inser­
tion of a replication defective promoterless retrovirus with   
a FlipROASCeoC-2 gene, containing a 3 splice acceptor and 
the coding region for a functional signal­anchor peptide/trans­
membrane domain in fusion with a Neo
r gene and strong tran­
scriptional terminators (De­Zolt et al., 2006). Analysis of the 
fusion cDNA expressed in ES cells predicted the insertion to 
have occurred in intron 14 and the mutant allele to direct the   
expression of a type I transmembrane fusion protein with an 
ectodomain comprised of aa 34–403 of mouse ERO1­ and a 
cytosolic portion with a functional Neo
r gene. Missing from the 
fusion protein are key structural elements that coordinate the 
FAD (flavin adenine dinucleotide) moiety required for enzy­
matic activity (Gross et al., 2004). Thus, the mutation is pre­
dicted to severely disrupt ERO1­ function.
Molecular analysis confirmed the insertion between exon 
14 and 15 of the gene but also called attention to the existence 
of additional ERO1-–homologous sequences in mouse chro­
mosome 13 involving the 3 portion of the gene (see Materials 
and methods). These homologous sequences were present in all 
mouse strains tested and in the sequenced genome of BL/6. The 
latter revealed several polymorphisms in the exonic DNA that 
distinguished the centromeric and telomeric versions of the   
duplicated sequences. Analysis of the mouse EST database and 
direct sequencing of cDNA from the pancreas of BL/6 mice   
revealed that only the centromeric ERO1- DNA was expressed 
as mRNA in the pancreas (unpublished data), indicating that the 
telomeric sequence is likely an intron­containing pseudogene 
and that the insertion in P077G11 could disrupt gene function.
Chimeric males derived by injection of P077G11 ES cells 
into  BL/6  blastocysts  transmitted  the  mutant  allele  to  their 
progeny. We exploited a polymorphism between the BL/6 and 
129 genome at the 3 end of exon 14 to mark the wild­type 
BL/6 allele and distinguish it from the mutant 129 allele. Thus, 
the presence or absence of a PstI site in genomic DNA derived 
by PCR from the 3 end of intron 14 was used to distinguish 
F2 progeny that were wild type (+/+), heterozygous (i/+), or 
homozygous for the insertion (i/i; Fig. 2 A and see Materials 
and methods).
Immunoblotting showed that the insertion strongly com­
promised  ERO1­  expression  in  the  pancreas  and  directed 
expression  of  the  predicted  ERO1­–Neo
r  fusion  protein   
(Fig. 2 B; the fusion protein was faintly visible at this exposure 
but more conspicuous in longer exposures). Immunostaining of 825 Islet dysfunction in Ero1lb mutant mice • Zito et al.
homozygous mutant, we established compound mutant mice 
with mutations in both ERO1 genes by crossing the ERO1­ 
mutation into a strain with an insertional mutation in intron 6 of 
Ero1l (derived from the ES cell line XST171) that encodes a non­
functional ERO1­ protein truncated at residue 168. Immuno­
blotting of pancreatic and spleen lysates from wild­type, ERO1­ 
mutant, ERO1­ mutant, and compound mutant mice con­
firmed the effect of the mutations on cognate protein expression 
but gave no evidence for compensatory increase in expres­
sion of one isoform when the other was lowered (Fig. 6 A).   
A similar observation was noted in the Min6 insulin­producing 
cell line (Fig. S4 A).
A similar lack of compensatory changes in isoform expres­
sion was noted in a different secretory cell type, immuno­
globulin­producing lipopolysaccharide (LPS) blasts produced 
by  exposure  of  spleen  cells  procured  from  individuals  with 
wild­type and mutant ERO1 genotypes to bacterial LPS in vitro.   
Wild­type LPS blasts expressed both ERO1­ and ­, but LPS   
blasts procured from animals with mutations in one isoform 
did not detectably up­regulate the expression of the other   
isoform (Fig. 6 B). It is notable that whereas in immunoblots 
of reduced and denatured lysates from wild­type cells, the 
ERO1­ antiserum recognized two close bands of nearly equal 
intensity, in samples from cells lacking ERO1­, the slower 
migrating form of ERO1­ predominated (Figs. 2 B and 6,   
A and B). The significance of this reproducible observation is   
presently unclear.
LPS­induced differentiation into metabolically active 
morphologically normal blasts (a process which takes 2–3 d) 
was unaffected by the deficiency in both isoforms of ERO1   
(unpublished data). And oxidative folding of IgM (the major   
secretory product of LPS blasts) was only modestly delayed by 
the compound mutation; this was revealed by comparing the 
rate at which oxidative forms of IgM were regenerated followed 
by their reduction in vivo by a 30­min DTT pulse (10 mM),   
removal of the reducing agent, and further culture for variable 
period of chase before lysis in the presence of N­ethyl maleimide 
and nonreducing SDS­PAGE (Fig. 6 C). Serum levels of IgM 
were likewise similar in the wild­type and compound mutant 
mice (Fig. 6 D). Furthermore, in keeping with the evidence 
for a surprisingly minor role for ERO1 in oxidative folding in 
immunoglobulin­secreting cells, there was no evidence for 
up­regulation of UPR target genes in the compound mutant LPS 
blasts (Fig. S4 B).
In the endocrine pancreas, too, there was no evidence for 
compensation by ERO1­ for the defect imposed by ERO1­ 
loss of function. This was assessed by comparing glucose toler­
ance of 2.5­mo­old wild­type male ERO1­ mutant and com­
pound ERO1­; ERO1­ mutant mice. At this age, the ERO1­ 
Figure 3.  Impaired glucose tolerance and glucose-stimulated insulin se-
cretion in ERO1- mutant mice. (A) Fasting blood glucose of male mice of 
the indicated age and indicated ERO1- genotype. Shown are the mean 
and SEM in each group; also shown (in small black dots) are the glu-
cose measurements of the individual mice in each group (*, P < 0.001).   
(B)  Fasting  blood  glucose  and  blood  glucose  to  serum  insulin  ratio  of   
6-mo-old male mice with the indicated ERO1- genotype. Shown are the 
mean and SEM in each group (n = 5; *, P < 0.001 by two-tailed t test). 
(C) Blood glucose levels after intraperitoneal injection of a glucose load 
into 6-mo-old male otherwise-isogenic C57BL/6; 129 F1 hybrid wild-type 
and heterozygous ERO1- mutant mice. Shown are the mean and SEM in 
each group (n = 5; *, P < 0.001 by two-way ANOVA). (D) Blood glucose 
to serum insulin ratio at the fasted and 15-min time point of the experi-
ment shown in C. Shown are the mean and SEM in each group (n = 5;   
*, P < 0.001 by two-tailed t test) and the measurement on each individual 
animal in small black circles.
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mutant mice had mild fasting hyperglycemia and significant   
intolerance to glucose load, but these features were not en­
hanced by concomitant disruption of ERO1­ (Fig. 6 E).
Attenuated ERO1- expression protects 
Min6 cells from the consequences of 
enforced expression of a misfolding-prone 
proinsulin but fails to protect islets of 
Langerhans against the same stress in vivo
Oxidative protein misfolding in the ER is deleterious to insulin­
producing  cell function and viability. This pathophysiological 
mechanism may be especially prominent in cells expressing 
mutant forms of insulin that are unable to undergo proper di­
sulfide bond formation (Wang et al., 1999; Liu et al., 2007). 
In yeast and worms, partial loss of function of the essential 
ERO1 gene enhances the organism’s ability to cope with severe 
ER stress (Haynes et al., 2004; Marciniak et al., 2004), which 
is noted in the face of significant levels of ER stress and strong   
activation of the UPR by compromised ERO1 function.
To  test  whether  partial  compromise  of  ERO1  activity 
may likewise protect  cells from severe ER stress, we sta­
bly lowered gene function by RNAi in Min6 cells, an insulin­ 
producing mouse insulinoma cell line. Like yeast and worms, 
Min6 cells with lowered ERO1­ activity had higher levels of 
transcriptional targets of the UPR (Fig. 7 A) and experienced   
delayed maturation of proinsulin compared with the parental cells   
(Fig. S5). ERO1­ knockdown Min6 cells were also strongly 
protected from the previously noted lethal consequences of   
expression  of  a  GFP­tagged  misfolding­prone  proinsulin
Akita 
(with a mutation, C96Y, precluding an essential disulfide bond; 
Wang et al., 1999; Oyadomari et al., 2002; Liu et al., 2007). This 
is evinced from the observation that stable colonies express­
ing  GFP­proinsulin
Akita  developed  very  inefficiently  in  wild­
type (parental) Min6 cells but readily formed in the ERO1­  
knockdown–derivative line KD1 (Fig. 7, B and C).
To determine whether lowered levels of ERO1­ can also 
protect  cells against lethal levels of ER stress in mice, we bred 
isogenic 129 mice carrying the mutant ERO1­ insertion allele 
to isogenic BL/6 mice that carried the proinsulin2
Akita mutation 
(Ins2
C96Y/+) and analyzed the compound phenotype in otherwise­
isogenic male F1 hybrid progeny. As reported previously (Wang 
et al., 1999), in the wild­type ERO1­ background, the pro­
insulin2
Akita mutation (Ins2
C96Y/+; ERO1­
+/+) resulted in a mild 
progressive  diabetic  phenotype,  whereas  Ins2
+/+;  ERO1­
i/+  
mice had normal fasting blood sugars (Fig. 3 C). However,   
surprisingly, compounding the proinsulin
Akita mutation with the 
ERO1­ mutation (Ins2
C96Y/+; ERO1­
i/+) exacerbated glucose 
Figure  4.  Diminished  insulin  stores  and  mildly  disorganized  islets  in 
ERO1- mutant mice. (A) Hematoxylin- and eosin-stained pancreatic sec-
tions of 3-mo-old wild-type and homozygous ERO1- mutant mice. (B) Pan-
creatic insulin content of mice as in A. Shown are the mean and SEM   
(n = 5; *, P < 0.001 by two-tailed t test). (C) Fluorescent micrographs of 
frozen section of pancreas from wild-type (+/+) and ERO1- homozygous 
mutant mice (i/i; as in A) stained with antisera to insulin (Ins), glucagon, 
and the karyophilic dye DAPI. The bottom right panel in each genotype is 
an overlay of the three stains. Note the presence of glucagon-positive cells 
in the interior of the islet of the ERO1- mutant. (D) Electron micrographs 
of  insulin-producing    cells  from  islets  of  Langerhans  of  wild-type  and   
ERO1- mutant mice. Note the lack of ER dilation in the higher magnifica-
tion views (right) of the mutant sample. Bars: (A and C) 100 µm; (D, left) 
2 µm; (D, right) 0.5 µm.
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intolerance (Fig. 7 D). This was noted in the face of similar   
reduction of islet mass in pancreatic sections (not depicted) 
and similar lowering (compared with Ins2
+/+) of pancreatic   
insulin content by expression of the proinsulin2
Akita in Ins2
C96Y/+; 
ERO1­
+/+ and Ins2
C96Y/+; ERO1­
i/+ mice (Fig. 7 E). Thus, the 
benefits of a more reducing ER on cells’ ability to cope with 
an oxidatively misfolded mutant proinsulin were apparent in   
cultured insulin­producing cells but not in the endocrine pancreas 
of live mice.
Discussion
This paper represents the first analysis of the consequences of 
disruption of ERO1 isoforms in living mammals. Our findings 
of direct oxidation of PDI by ERO1­ in vitro and retarded oxi­
dative folding of proinsulin in islets lacking ERO1­ are consis­
tent with a simple model in which ERO1­ is an important 
disulfide oxidase in insulin­producing  cells. Insulin biosynthe­
sis is dynamically regulated, with up to a sixfold increase in the 
translation rate in response to physiological excursions in glu­
cose levels (Itoh and Okamoto, 1980). Proinsulin is the major 
biosynthetic product of the  cell, and its efficient oxidative fold­
ing may represent a significant quantitative challenge to the ER 
machinery. Thus, our findings are readily explained by a gene 
duplication event, giving rise to an islet­selective isoform of the 
ERO1 oxidase that boosts the oxidative folding capacity of insulin­
producing cells through gene dosage effects.
Islets explanted from homozygous ERO1­ mutant mice 
(and ERO1­–deficient Min6 cells) have a conspicuous kinetic 
defect (delay) in oxidative folding and proinsulin maturation. 
More aberrant oxidized folding intermediates of proinsulin are 
also observed in islets explanted from mutant mice. Further­
more, in the insulin­producing  cell line Min6 conspicuous   
induction of UPR targets is observed after ERO1­ knockdown. 
Together, these observations suggest that the enhanced load of 
unfolded intermediates in insulin­producing cells that lack 
ERO1­ challenges the protein folding environment of their ER. 
A similar activation of the UPR is observed in yeast and worms 
with partial loss of ERO1 function (Frand and Kaiser, 1998; 
Pollard et al., 1998; Marciniak et al., 2004).
Morphological disorganization of the islets (reflected in 
the presence of glucagon­producing cells in their interior) sug­
gests ongoing degeneration. However, this feature is mild at 
worse, as the diabetic phenotype of the homozygous mutant, 
once established at 3 mo, does not progress. Furthermore,   
although the delayed maturation of proinsulin and other pro­
teins that fold oxidatively is likely to enhance the steady­state 
levels of misfolded proteins in the mutant cells’ ER, the ERO1­ 
mutation we studied is not associated with the conspicuous   
ultrastructural changes that have been noted in other diseases of 
Figure 5.  Delayed and inefficient oxidative maturation of proinsulin in 
ERO1-  mutant  islets  of  Langerhans.  (A)  Autoradiograph  of  proinsulin 
(ProIns) and insulin (Ins) immunoprecipitated from lysates (top) and culture 
supernatant (media; bottom) of islets isolated from mice with the indicated 
ERO1- genotype, metabolically labeled with [
35S]methionine/cysteine for 
a 20-min pulse, followed by the indicated chase period. Immunopurified 
proteins were resolved on a reducing tris-tricine gel, and their position on 
the gel is indicated. (B) The ratio of mature insulin to total (proinsulin and 
insulin) signal of the experiment shown in A is plotted as a function of time. 
(C) Autoradiograph of proinsulin immunoprecipitated from lysates of islets 
of the indicated ERO1- genotypes metabolically labeled as in A. The 
immunopurified proteins were resolved on a nonreducing tris-tricine gel. 
Shown are the positions of the reduced proinsulin (ProIns
red; indicated by 
the migration of a reduced sample loaded at a distance on the same gel, 
lane 1), oxidized proinsulin (ProIns
ox), and higher molecular mass oxidized 
species. The bottom panel is a Coomassie blue stain of the same gel. The 
vertical black line indicates that intervening lanes have been spliced out. 
(A and C) Molecular mass is indicated in kilodaltons. (D) The ratio, as 
a function of time, of oxidized proinsulin to total label in the proinsulin   
immunoprecipitation in the experiment shown in C is shown.
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on glycemic control of the ERO1­ mutant. More surprising, 
LPS blasts (and their immunoglobulin­producing counterpart   
in vivo) are able to produce nearly wild­type levels of IgM   
despite mutation of both ERO1 isoforms. These findings point 
strongly to the existence of hitherto unanticipated, ERO1­ 
independent mechanisms to generate disulfide bonds in mam­
malian cells. Redundant mechanisms for disulfide bond formation 
may also exist in more distant organisms such as in flies, as attested 
to by the viability of clones with homozygous deletion of that 
ER protein misfolding (Wang et al., 1999; Harding et al., 2001; 
Zhang et al., 2002).
The mutant phenotype may be explained by a global   
inefficiency in the ERO1- mutant islet cell’s ER to pass elec­
trons from its pool of reduced PDIs to their terminal acceptors. 
However, this simple model is challenged by the surprising   
nonredundancy of the ERO1­ and ­ isoforms, although both 
are expressed in the pancreas (Fig. 1 A) and in Min6 cells   
(Fig. S4 A). Concomitant depletion of ERO1­ has no effect 
Figure 6.  Disulfide bond formation despite disruption 
of both ERO1- and -. (A) Immunoblot of ERO1- (top), 
ERO1- (middle), and Ribophorin I (bottom) in pancre-
atic and splenic membrane fractions of mice with the 
indicate ERO1- and - genotypes. Note that the levels 
of one ERO1 isoform do not change in response to 
decline in the other isoform. The asterisk marks a non-
specific band detected by the anti–ERO1- serum in 
pancreas. (B) Immunoblots of ERO1 isoforms and PDI 
in lysates of LPS-induced B cell blasts of the indicated 
genotypes. To facilitate the comparison, three different 
loadings of each sample were analyzed. (C) Immunoblot 
of IgM from lysates of wild-type and compound mutant   
ERO1-
i/i; ERO1-
i/i LPS blasts after 30-min exposure 
to DTT in vivo and the indicated period of washout. The 
rate of recovery of disulfide bonds in IgM is reported 
on by the progressive depletion of monomers (1µ) and 
assembly of dimers (2µ) and pentamers (5µ) on this 
nonreducing gel. The sample in lane 1 is from cells that 
had never been exposed to DTT. A reducing gel with a 
fraction of the same samples is presented in the bottom 
panel. (A–C) Molecular mass is indicated in kilodal-
tons. (D) Serum IgM in 3-mo-old wild-type and com-
pound mutant ERO1-
i/i; ERO1-
i/i mice. Shown are 
the mean and SEM (n = 3). (E) Blood glucose concen-
tration after a glucose injection (as in Fig. 3 C) in mice 
with the indicated genotypes. Shown are the mean and 
SEM (n = 3; *, P < 0.001 by two way ANOVA; †, no 
significant difference).829 Islet dysfunction in Ero1lb mutant mice • Zito et al.
species’ single ERO1 gene (known as kiga; Tien et al., 2008) 
Furthermore, the differences between  cells and immunoglobulin­ 
producing cells highlight the special role of ERO1­ in disul­
fide bond formation and protein folding homeostasis in the 
lumen of the ER of insulin­producing cells.
At present, we have few experimentally derived clues to 
the special features of ERO1­ that render it critical to the proper 
function of the  cell ER. In vitro, purified ERO1­ and ­ have 
similar capability to accept electrons from a model substrate 
(reduced bacterial thioredoxin) or a physiological substrate   
(reduced human PDI1). However,  cells have a peculiar com­
plement of PDIs (Fig. 7 A; Dias­Gunasekara et al., 2005) that 
may be better suited to work with ERO1­ than ERO1­. Such 
specialization, if it exists, may have arisen because of differ­
ences in the regulation of the two ERO1 isoforms by redox. Yeast 
ERO1 is allosterically regulated by the oxidation of regulatory 
cysteines (Sevier et al., 2007). These are conserved in function 
in ERO1­, but their counterpart in the ERO1­ sequence may 
be missing (Appenzeller­Herzog et al., 2008; Baker et al., 2008). 
Thus, it is tempting to speculate that the dramatic physiologi­
cal excursions of proinsulin translation may have favored the 
evolution of a specialized nonredundant system for disulfide 
bond formation in  cells.
Simple eukaryotes like yeast, worms, and flies have a single 
ERO1 gene that maintains the oxidizing environment in their 
ER by transferring electrons from reduced PDI­like molecules 
to terminal electron acceptors. The oxidized and reduced forms 
of the PDIs are in equilibrium with their reduced clients and 
with  small  molecule  redox  buffers  like  reduced  glutathione 
(Cuozzo and Kaiser, 1999). Thus, in these simple eukaryotes, 
ERO1 activity maintains a global redox equilibrium in the ER 
lumen that favors native disulfide bond formation and yet is   
permissive for the reshuffling and reduction of nonnative bonds.
The aforementioned model of a global redox equilibrium 
maintained by ERO1 is consistent with the observations that   
in yeast and worms, partial loss of function of the essential 
ERO1 gene enhances the organism’s ability to cope with severe   
ER stress. Thus, ero1-1 mutant yeast are better able to cope 
with the overexpression of a disulfide­containing, misfolding­
prone mutant lysosomal peptidase, CPY*, under conditions of 
compromised degradation of the misfolded proteins in the ER   
Figure 7.  Lowering ERO1- levels protects Min6 cells from the conse-
quences of expression of a misfolding-prone proinsulin mutant but does 
not preserve islet function in mice. (A) RNAi knockdown of ERO1- in 
Min6  cells  revealed  by  immunoblotting  (left)  or  immunostaining  (right). 
Also shown is an immunoblot of the UPR targets, GRP94, immunoglobulin-
binding protein (BIP), and PDI in the parental Min6
WT cells and two RNAi 
knockdown cell lines (Min6
KD1 and Min6
KD2). -Actin serves as a loading 
control. Molecular mass is indicated in kilodaltons. (B) Photomicrographs 
of crystal violet–stained parental and ERO1- knockdown (KD1) Min6 cells 
after transduction with a blasticidin resistance–marked lentivirus express-
ing either GFP or a fusion of GFP with a mutant proinsulin
Akita GFP-INS
C96Y 
(Liu et al., 2007). Where indicated, the cells were selected for blasticidin 
resistance. (C) As in B; quantification of the cell mass after transduction 
of the parental (Min6
WT) or ERO1- knockdown (Min6
KD1) cells with the 
GFP lentivirus (set at 100%) or the GFP-INS
C96Y lentivirus and blasticidin 
selection for 7 d (shown are the mean and SEM; n = 3; *, P < 0.02).   
(D) Fasting blood glucose of a cohort of male Akita (Ins2
C96Y) mutant mice 
with the indicated ERO1- genotypes at the indicated age. Shown are the 
mean and SEM of each group as well as the measurements in each indi-
vidual mouse (in small black dots; n = 4; *, P < 0.009; and **, P < 0.003 
by two-tailed t test). (E) Insulin content of pancreas from 2-mo-old male mice 
of the indicated Ins2 and ERO1- genotype. Shown are the mean and SEM 
(n = 3; *, P < 0.005 by two-tailed t test). Bars: (A) 25 µm; (B) 1 mm.
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(Sigma-Aldrich) affinity gel overnight, eluted in 10 mM EDTA, 20 mM Tris, 
pH 7.5, and 0.002% Tween 20, and used in the enzyme assays shown in 
Fig. 1 D and Fig. S2. In brief, the indicated concentrations of ERO1,   
reduced E. coli thioredoxin A (TrxA) or human reduced PDI expressed in 
and purified from E. coli transduced with expression plasmids (gifts from   
D. Fass [Weizmann Institute of Science, Rehovot, Israel] and C. Thorpe 
[University of Delaware, Newark, DE], respectively), were combined in a 
20-µl reaction in a 384-well format. After the addition of 0.1 U/ml horse-
radish peroxidase (Worthington Biochemical Corp.) and 10 mM Amplex 
Ultra red (Invitrogen), the H2O2 produced was detected as the time- 
dependent fluorescent signal on a microplate reader (F500; Tecan; excitation 
wavelength, 535 ± 20 relative fluorescent units; and emission wavelength, 
590 ± 20 relative fluorescent units).
Animal breeding and genotyping
All  experiments  performed  on  mice  were  approved  by  New  York   
University’s Institutional Animal Care and Use Committee. The P077G11   
mouse ES clone with a presumptive promoter trap retroviral insertion 
into intron 14 of the Ero1lb (ERO1-) locus was purchased from the 
German Gene Trap Consortium. After blastocyst injection, the mutant   
allele was transmitted to 129svev mice and maintained in that inbred   
background. The presence of the mutant allele was detected by geno-
mic PCR using primers that recognize the FlipROASCeoC-2 retroviral   
insert (hCD2.3S, 5-GGAGACAAGAGCCCACAGAGTAGCTAC-3; and 
Neo.10AS, 5-AGTCCCTTCCCGCTTCAGTGACAACGT-3), giving rise 
to a 301-bp product.
The additional homologous sequence telomeric of the ERO1- locus 
presented  a  challenge  to  distinguishing  heterozygous  from  homozygous 
mutant mice. Therefore, 129svev carriers of the insertion were crossed to 
wild-type C57BL/6 mice and the F1 carriers identified, as shown in Fig. 2 A.   
To genotype F3 progeny, we exploited a sequence polymorphism in intron 
14: the presence of a PstI site in the 129 but not C57BL/6 genome on 
a  PCR  fragment  amplified  with  the  primers  ERO1-.21S  (5-TGGGTGT-
GTCCACCGAGGCAGTGGA-3)  and  ERO1-.18AS  (5-GATCTTCAAG-
GCAGTTCCTAAACCCTGAG-3) that is tightly linked to the insertion. Thus, 
inheritance of two 129 copies of chromosome 12 in F2 hybrids is an indica-
tion of homozygosity for the mutation, whereas inheritance of two C57BL/6 
versions of the chromosome marks the animal as wild type. Meiotic recom-
bination between the insertion and marker was excluded by measuring   
ERO1- protein in mouse tissue after analysis.
In brief, germ line transmission of a promoter trap insertion in ES 
clone XST171 (purchased from BayGenomics) was confirmed to have 
occurred in intron 6 and noted to eliminate >95% of protein expression 
in  stressed  cells.  The  mutation  was  maintained  by  backcrossing  to 
C57BL/6. The mutation and the wild-type alleles were distinguished by 
genomic PCR using the primers mERO1-.11S (5-CTCAAAGGTGTA-
CAGCACGGCCAACTCATATTTTC-3), mERO1-.10AS (5-AGGGTTAA-
GGAGTAAGTCCACATACTCAGCATCG-3), and AMP.4AS (5-ACCAG-
CGTTTCTGGGTGAGCAAAAACAGGAAGG-3). The wild-type allele gives 
a mERO1-.11S versus mERO1-.10AS product of 220 bp, whereas the 
mutant allele gives an AMP.4AS versus mERO1-.10AS product of 800 bp.
Akita mice bearing the Ins2
C96Y mutation were purchased from The 
Jackson Laboratory and genotyped as previously described (Wang et al., 
1999). They were crossed to 129svev heterozygous ERO1-
i/+ mice, and 
otherwise-isogenic C57BL/6; 129svev F1 hybrid carriers of the Akita muta-
tion, discordant for the ERO1- insertion, were evaluated.
Purification of microsomes from mouse tissues
Tissues were mechanically disrupted by a Teflon homogenizer in 20 mM 
Hepes, pH 7.4, 5 mM MgCl2, 0.3 M sucrose, and protease inhibitors. 
The postmitochondrial supernatant was isolated by gentle clarification 
at 8,000 g for 5 min, and the microsomes were recovered by pellet-
ing at 100,000 g for 30 min. The amount of ERO1- in the micro-
somes was measured by immunoblot with an infrared imaging system   
(Odyssey; LI-COR).
Blood glucose and insulin measurement
Blood glucose levels were measured with a portable glucose-measuring 
device (OneTouch Ultra; LifeScan, Inc.). Insulin levels were measured by 
ELISA (EZRMI-13K; Millipore), using mouse insulin as standard. Intraperito-
neal glucose tolerance tests were performed on animals that had been 
fasted for 16 h and were injected intraperitoneally with glucose, 2 mg/g 
body mass.
Pancreata were removed and immediately frozen in liquid nitro-
gen. Protein extracts were prepared using the acid/ethanol method 
(http://www.amdcc.org/shared/showFile.aspx?doctypeid=3&docid=73).
(Haynes et al., 2004). In worms, ero-1(RNAi) enhances life­
span of adults exposed to tunicamycin, an inhibitor of N­linked 
glycosylation which induces severe ER stress (Marciniak et al., 
2004). These benefits to the mutant accrue in spite of the ER 
stress that partial loss of ERO1 function promotes and have been 
attributed to rectification of failures of homeostasis, whereby 
ongoing disulfide oxidation and the attendant production of 
H2O2 by ERO1 challenges the cellular reserves for coping 
with such stress in the wild type. Additionally, the physical 
properties of misfolded ER proteins may be influenced by their 
oxidative state, with disulfide bonds stabilizing the misfolded 
conformation (Marciniak et al., 2004).
Consistent with these ideas, we observed that compromise 
of ERO1­ in cultured Min6 cells enhanced their ability to cope 
with enforced expression of a mutant misfolded proinsulin
Akita. 
However, surprisingly, this benefit was not realized in mutant 
mice: both mild compromise to ERO1­ by heterozygosity of 
the P077G11 insertion allele (Fig. 7, D and E) and severe   
compromise by homozygosity (not depicted) accentuated the 
diabetic phenotype of the Ins2
Akita mutation.
What may account for these differences in the outcome of 
ERO1­ loss of function in the two systems? The higher oxygen 
concentration that cultured cells were exposed to, compared 
with tissues, may place a premium on lowered levels of ERO1­ 
in the former. Differences in activation of cell death pathways 
(by ER stress) in immortalized cultured cells and their tissue 
counterparts  may  contribute.  Insulin  signaling  may  have  an   
important autocrine role (Leibiger et al., 1998; Leibiger et al., 
2001) that would be realized in the tissue but not in cells   
(growing in serum). This would attach a cost to the defect in   
insulin biogenesis (which is triggered by ERO1­ deficiency) 
that is evident in tissues but not in cells. It is also possible that 
the  constitutive  lowering  of  ERO1­  activity  by  the  mutant   
allele perturbs developmental programs, offsetting, in the live 
animal, the benefit of a less oxidizing ER that is realized in 
stressed cultured cells. Transient inhibition of ERO1 with 
chemicals may provide a way to test some of these ideas.
Materials and methods
Recombinant proteins and antisera
Antisera were purchased and used in according to the vendor’s specification: 
anti-PDI (Stressgen), anti-KDEL (Stressgen), anti–-actin (Sigma-Aldrich), 
anti–bovine insulin (Millipore), and anti–mouse IgM (Rockland). Rabbit 
antiserum to Ribophorin I was a gift from G. Kreibich (New York University, 
New York, NY).
Antisera to mouse ERO1- and - were raised in rabbit by immuni-
zation with mouse ERO1- (23–464) and ERO1- (39–467) expressed as 
a  GST-Smt3  fusion  proteins  in  the  Escherichia  coli  Rosetta  (D3)  strain,   
followed by glutathione affinity chromatography, cleavage of the tag with 
Ulp1, and gel filtration on a Superdex 200 (GE Healthcare). The soluble 
ERO1- retained its enzymatic activity (Fig. 1 D), whereas ERO1- rapidly 
lost enzymatic activity but remained useful as an immunogen.
Immunopurification of Flag–ERO1-, –ERO1-, and –ERO1-
C396A  
and enzyme assays
Expression plasmids encoding ER-localized, N-terminally Flag-tagged mouse 
ERO1-  (23–464)  and  ERO1-  and  ERO1-
C396A  (39–467)  were  con-
structed in the pFlag-CMV1 vector (Sigma-Aldrich) and transfected into 
293T cells. Cell lysate was prepared in Triton buffer (0.3% Triton X-100, 
150 mM NaCl, 20 mM Hepes, pH 7.4, 10 mM CaCl2, and protease   
inhibitors). The Flag-tagged proteins were immunopurified with Flag M1 831 Islet dysfunction in Ero1lb mutant mice • Zito et al.
Online supplemental material
Fig.  S1  shows  experiments  on  the  reactivity  of  the  ERO1-  and  -  
sera. Fig. S2 shows experiments the on specificity of the assay for measuring 
the in vitro disulfide oxidase activity of ERO1. Fig. S3 shows experiments 
on the insulin content in the pancreas of otherwise-isogenic wild-type and 
heterozygous mutant ERO1- mice. Fig. S4 is a further characterization 
of the ERO1- knockdown Min6 cells, and Fig. S5 is a characterization 
of insulin maturation in these cells. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.200911086/DC1.
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After  neutralization,  insulin  in  the  extracts  was  measured  by  ELISA.   
Protein in tissue extracts was determined by the Bradford method.
Immunostaining
Mice were killed by CO2 asphyxiation, and tissues were fixed by car-
diac perfusion with 4% paraformaldehyde in PBS. After rinsing in PBS, 
tissues were incubated overnight in 30% sucrose and embedded in opti-
mal cutting media. Insulin and glucagon immunoreactivity were detected 
by incubating 5-µm thick frozen sections of mouse pancreas with anti- 
insulin (Millipore) diluted 1:4,000, rabbit antiglucagon (Invitrogen) diluted 
1:500, or rabbit anti–ERO1- diluted 1:300, followed by FITC-conjugated 
anti–guinea pig IgG or Texas red–conjugated anti-rabbit IgG (Jackson 
ImmunoResearch Laboratories). Slides were mounted in CitiFluor. Fluorescent   
images were visualized at room temperature on a microscope (Axioplan-100; 
Carl Zeiss, Inc.) using a 40× NA 1.3 oil Plan-NeoFluar objective (Carl 
Zeiss, Inc.) and acquired on a monochrome charge-coupled device cam-
era (SPOT RT-SE6 1.4 MP; Diagnostic Instruments, Inc.) using SPOT Basic 
software (Diagnostic Instruments, Inc.), and overlays were created in 
Photoshop (Adobe).
Transmission electron microscopy
Pancreatic tissue was fixed by immersion in 2.5% glutaraldehyde in 0.1 M   
Sorensen buffer, postfixed in 1% osmium tetroxide, and en bloc stained 
with 3% uranyl acetate. The tissue was dehydrated in ethanol embedded   
in epon. Ultrathin sections were poststained with uranyl acetate and lead   
citrate and examined using an electron microscope (CM100; Philips) at 60 kV.   
Images  were  recorded  digitally  using  a  camera  system  (1.6  Megaplus;   
Kodak) with software from Advanced Microscopy Techniques Corp.
Isolation, culture, and metabolic labeling of mouse pancreatic islets
Islets of Langerhans from wild-type and ERO1- mutant mice were isolated 
using collagenase-P (Roche) and purified using three benchtop sedimenta-
tions and three selections by handpicking. Islets were cultured for 20 h in 
RPMI-1640 (Invitrogen) containing 10% FCS (Hyclone).
Islets were preincubated in methionine-free RPMI-1640 medium 
for 1 h and then labeled in the same medium containing 60 µCi/ml 
[
35S]methionine/cysteine (PerkinElmer; specific activity, >1,000 Ci/mmol). 
Cold chase was performed in complete (methionine containing) medium. 
Islets were lysed on ice for 10 min in 500 µl lysis buffer (50 mM Tris-HCl, 
pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1% Na deoxycho-
late, and protease inhibitors). Islet lysates were precleared by centrifuga-
tion at 4°C for 10 min at 15,000 g, followed by immunoprecipitation of 
the supernatant (2 h at 4°C) using 5 µl anti-insulin (which is also reactive 
with proinsulin). Immunoprecipitated proteins were resolved on a 15%   
tricine-urea-acrylamide gel and revealed by autoradiography with a 
phosphoimager (Typhoon; GE Healthcare).
LPS blasts
Splenic cells were cultured in RPMI-1640 at a density of 10
6 cells/ml and 
exposed to 50 µg/ml LPS from E. coli (Sigma-Aldrich), to activate B cell 
differentiation. Where indicated, cells were exposed to a 30-min pulse of   
10 mM DTT, washed free of DTT, and cultured further until lysis (in the 
presence of 10 mM N-ethyl maleimide), nonreducing SDS-PAGE, and 
anti–mouse IgM immunoblot.
Min6, knockdown of ERO1-, and lentiviral transduction
Min6 cells were cultured in DME supplemented with 25 mM glucose, 10% 
FCS, and 55 µM -mercaptoethanol. ERO1- knockdown was achieved 
using Mission short hairpin RNA (shRNA)–encoding lentiviruses directed 
to mouse Ero1lb mRNA (Sigma-Aldrich; GenBank/EMBL/DDBJ accession   
no. NM_026184) according to the manufacturer’s instructions. Knock-
down clone KD1 was targeted with shRNA TRCN0000100896, and KD2 
was targeted with shRNA TRCN0000100899.
Blasticidin resistance–marked lentiviruses encoding GFP (pLenti 6.3V5- 
TOPO; Sigma-Aldrich) or GFP-tagged human proinsulin
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